The test, developed with Pfizer, could identify renal cancer patients who would experience recurrence, but not who would benefit from adjuvant Sutent.
Dubbing itself a "telegenomics company," San Francisco startup Genome Medical announced the launch this week of its genetic consultation services offering.
The telegenomics startup will use the proceeds to support the rollout of its genetic consultation services. A pilot version of the services was launched last fall.
The company will return both a genomic prediction of disease aggressiveness and a read on 10-year risks for metastasis and for disease-specific mortality.
The company missed analyst estimates on the top line but beat the bottom line with growth in prostate cancer and international breast cancer test sales.
The Medicare contractor proposed coverage for several cancer assays, but would not cover molecular respiratory virus assays or a test for inflammatory bowel disease.
In a note to investors, the investment bank said the company is going through a transition phase, and has limited potential for near-term upside.
The company plans to use proceeds to advance its lead AR-V7 test with Genomic Health, accelerate other assays in its pipeline, and enhance its technology.
Gencurix aims to achieve US FDA 510(k) clearance for its GenesWell BCT breast cancer prognostic test next year.
The company beat the consensus Wall Street estimate for the fourth quarter on the bottom line but missed the estimate on the top line.
A former Penn State Hershey Medical Center staffer has admitted to lying about skipping mandatory steps of genetic cancer tests he performed, the Associated Press reports.
The genome of a rare, red bat suggests that its effective population size has been in decline for thousands of years, according to a PLOS One study.
In Nature this week: investigation into the genetics of medulloblastoma, and more.
A project in the UK is to use genomic selection to speed spruce tree growth, according to Innovators Magazine.